The Association of Gut Microbiota With COVID 19 Infection in Children
Launched by HALLYM UNIVERSITY KANGNAM SACRED HEART HOSPITAL · Mar 28, 2022
Trial Information
Current as of May 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how the bacteria in our gut, known as the gut microbiome, may affect how children experience COVID-19 infections. Researchers want to understand if changes in the gut bacteria of children with COVID-19 can influence how sick they get or how long they stay in the hospital. The study is currently looking for participants, specifically children who have tested positive for COVID-19.
To be eligible for this trial, children must be infected with COVID-19, but those with certain health issues—like heart, kidney, or intestinal diseases, cancers, or immune system disorders—cannot participate. If children join the study, they will provide samples of their stool, which will help researchers analyze the gut bacteria before and during their hospital stay. This research aims to learn more about the connection between gut health and COVID-19, potentially leading to better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients infected with COVID 19
- Exclusion Criteria:
- • congenital heart, renal, intestinal disease
- • malignancy
- • immunologic disease
About Hallym University Kangnam Sacred Heart Hospital
Hallym University Kangnam Sacred Heart Hospital is a prestigious medical institution located in Seoul, South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a leading sponsor of clinical studies, the hospital integrates cutting-edge medical technologies and a multidisciplinary approach to provide high-quality patient care. With a focus on enhancing treatment outcomes and contributing to medical knowledge, Hallym University Kangnam Sacred Heart Hospital collaborates with various stakeholders to ensure the rigorous execution of clinical trials, adhering to the highest ethical and regulatory standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
KY YOUNG CHO, MD, PhD
Principal Investigator
Hallym University Kangnam Sacred Heart Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials